All News
Celecoxib Shines and Naproxen Tanks in the PRECISION Study
The PRECISION trial was published this week in the NEJM, presented at the Cardiology meetings in New Orleans, and presented today by Dr. Daniel Solomon at the 2016 ACR annual meeting in Washington, D.C. (citation source http://buff.ly/2fUmoqO)
Read Article
Guselkumab Efficacy and Tolerability in PsA/PsO
New treatment options for psoriatic arthritis continue to be explored at this year’s ACR/ARHP Annual Meeting in Washington, DC. Guselkumab (GUS) is a fully human monoclonal antibody against the p19 subunit of IL-23.
Read Article
Maintenance of Remission in ANCA-vasculitis: MAINRITSAN study.
It is well known that ANCA-associated vasculitides can be hard to control and relapses are common. The choice of maintenance therapy is rather limited and therapies are not always effective.
Read Article
Two New Biologics for Polyarticular JIA
On Monday, November 13, there were two new presentations at the annual ACR 2016 meeting on new biologics seeking approval for use in polyarticular juvenile arthritis.
Read Article
The Long Awaited PRECISION Study
The PRECISION study will be presented on Tuesday, November 15, 2016 by Dr. Elaine Husni from the Cleveland Clinic. This report brings to a climax the controversy ignited by the February 2005 3 day FDA Arthritis Advisory Committee review of the safety of the blockbuster COX-2 inhibitors, celecoxib, rofecoxib, and valdecoxib.
Read Article
Pfizer Features Xeljanz Presentations at ACR 2016
At this years 2016 ACR/ARHP Annual Meeting Pfizer will presen 20 abstracts, mostly centering around its JAK inhibitor tofacitinib (Xeljanz). They will also present the results of their Phase 3 OPAL studies of tofacitinib in patients with psoriatic arthritis.
Read Article
Lilly Features it's Rheumatoid and Psoriasis Biologics at ACR 2016
Eli Lilly & Co. has multiple presentations planned for the upcoming Annual meeting of the ACR/ARHP in Washington starting on Sunday, November 13th.
Read Article
Janssen's Portfolio of New Biologics Roll Out for ACR 2016
Janssen has announced the listings for it's presentations at the upcoming annual ACR/ARHP 2016 meeting in Washington.
Read Article
Creaky Joints Presentations at the ACR16 Meeting
CreakyJoints will be presenting 5 Posters at the 2016 ACR/AHRP Annual Meeting. At the meeting they will also announce the publication of first-ever Rheumatoid Arthritis Patient Guidelines.
Read Article
Genentech Presents New Data on Actemra & Rituxan at ACR 2016
At the upcoming 2016 ACR/ARHP Annual Meeting, Genentech will present 15 oral presentations from 17 abstracts relating to the use of tocilizumab and rituximab in a number of varied autoimmune conditions.
Read Article
Crescendo and Vectra Presentations at ACR 2016
Crescendo Bioscience has announced that it will have 4 poster presentations at the American College of Rheumatology 2016 Annual Meeting next week.
Read Article
Enbrel Approved for Pediatric Chronic Plaque Psoriasis
Etanercept (Enbrel) received FDA approval Friday for use in children with moderate to severe, chronic plaque psoriasis. Previously approved for adults with plaque psoriasis the new indication will be for chronic plaque psoriasis for those over age 4 years.
Read Article
RheumNow Week in Review – 4 November 2016
Dr. Jack Cush reviews highlights and reports from this week on RheumNow.com, including drug-induced cutaneous lupus, pediatric lupus being worse, new gout drug SEL-12, Gut microbiome and IgA plasmablasts, and the weakly-received new ACP guidelines on gout.
Read Article
ACP Gout Guidelines Reviewed and Critiqued by Rheumatologists
ACP released clinical practice guidelines for the diagnosis and management of gout. Interestingly, these are not always aligned with the 2012 ACR gout guidelines.
Read Article
When Cheap Generics Morph Into Expensive Prescriptions
The Wall Street Journal has reported an alarming trend in generic drug pricing that affects many, especially the elderly and those with arthrtis.
Read Article
POSTURE Study: Apremilast Fails in Ankylosing Spondylitis
ClinicalTrials.gov has listed the results of the POSTURE study, a large randomized placebo-controlled trial wherein apremilast was found to yield no benefit (compared to placebo) in treating ankylosing spondylitis (AS) (32.5% vs. 36.6% ASAS20 at week 16) patients.
Read Article
A Neural Signature in Fibromyalgia
Fibromyalgia is a well characterized condition with disordered pain processing. Although the clinical constellation and diagnostic clues are well characterized, FM lacks a diagnostic biomarker and most imaging and tissue diagnostics have been unrevealing.
Read Article
Nor-Switch Study Shows it's Safe to Switch to a Biosimilar
The results of the Nor-Switch study were presented at the United European Gastroenterology annual congress this week demonstrating no significant difference in effect, adverse effects or antibody formation in patients switched from Remicade to the biosimilar infliximab (CT-P13, Remsima).
Read Article
Inflectra Biosimilar Ships in Late November 2016
Pfizer has announced it will ship its new FDA-approved biosimilar, Inflectra, in late November and that it will be priced at a15 percent discount to current wholesale prices.
Read Article
RheumNow Week in Review – 14 October 2015
Dr Jack Cush reviews highlights from the news and journal articles appearing this week on RheumNow.com:
Read Article
